Search

Displaying results 3001 - 3010 of 5506 in total
  1. Drug

    Sulfoxone

    go.drugbank.com/drugs/DB01145
    Approved

    It has been used with limited success in the treatment of dermatitis herpetiformis.

  2. Drug

    D-3082-L

    go.drugbank.com/drugs/DB17440
    Experimental

    D-3082-L is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.

    Synonyms: Human Papilloma Virus (HPV) Type 16 E6/e7 Synthetic Long Peptide (SLP) Vaccine Component D-3082-L
  3. Drug

    Meticrane

    go.drugbank.com/drugs/DB13284
    Approved

    It has been marketed in Japan under the trade name Arresten and is used to lower blood pressure [L5647].

  4. Drug

    Tromantadine

    go.drugbank.com/drugs/DB13288
    Approved

    It is an antiviral used in the treatment of herpes zoster and simplex.

  5. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Upon division and maturation at the bone marrow following intravenous administration to the patient, hematopoietic progenitor cells enter the systemic circulation to restore blood counts and function [ … The unrelated donor transplant setting has several advantages over related donor transplant and bone marrow transplantation; it allows shorter time to transplant and tolerance of 1–2 human leukocyte antigen

  6. Drug

    Pimethixene

    go.drugbank.com/drugs/DB13292
    Approved

    It is an anticholinergic used in the treatment of bronchitis.

  7. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    Interestingly, when [risperidone] was created, Janssen suggested it was a more potent version of pipamperone. … It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518].

  8. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. … [A186071] It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.

  9. Drug

    Mibefradil

    go.drugbank.com/drugs/DB01388
    ApprovedWithdrawn

    Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

  10. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    It contains 6 N-linked oligosaccharide modification sites. … The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.